Valle-León Marta, Casajuana-Martin Nil, Del Torrent Claudia Llinas, Argerich Josep, Gómez-Acero Laura, Sahlholm Kristoffer, Ferré Sergi, Pardo Leonardo, Ciruela Francisco
Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, 08907 L'Hospitalet de Llobregat, Spain; Neuropharmacology and Pain Group, Neuroscience Program, Institut d'Investigació Biomèdica de Bellvitge, IDIBELL, 08907 L'Hospitalet de Llobregat, Spain.
Laboratory of Computational Medicine, Biostatistics Unit, Faculty of Medicine, Universitat Autònoma Barcelona, Bellaterra, 08193 Barcelona, Spain.
Biomed Pharmacother. 2023 Apr;160:114327. doi: 10.1016/j.biopha.2023.114327. Epub 2023 Feb 1.
The striatal dopamine D receptor (DR) is generally accepted to be involved in positive symptoms of schizophrenia and is a main target for clinically used antipsychotics. DR are highly expressed in the striatum, where they form heteromers with the adenosine A receptor (AR). Changes in the density of AR-DR heteromers have been reported in postmortem tissue from patients with schizophrenia, but the degree to which AR are involved in schizophrenia and the effect of antipsychotic drugs is unknown. Here, we examine the effect of exposure to three prototypical antipsychotic drugs on AR-DR heteromerization in mammalian cells using a NanoBiT assay. After 16 h of exposure, a significant increase in the density of AR-DR heteromers was found with haloperidol and aripiprazole, but not with clozapine. On the other hand, clozapine, but not haloperidol or aripiprazole, was associated with a significant decrease in AR-DR heteromerization after 2 h of treatment. Computational binding models of these compounds revealed distinctive molecular signatures that explain their different influence on heteromerization. The bulky tricyclic moiety of clozapine displaces TM 5 of DR, inducing a clash with AR, while the extended binding mode of haloperidol and aripiprazole stabilizes a specific conformation of the second extracellular loop of DR that enhances the interaction with AR. It is proposed that an increase in AR-DR heteromerization is involved in the extrapyramidal side effects (EPS) of antipsychotics and that the specific clozapine-mediated destabilization of AR-DR heteromerization can explain its low EPS liability.
纹状体多巴胺 D 受体(DR)通常被认为与精神分裂症的阳性症状有关,并且是临床使用的抗精神病药物的主要靶点。DR 在纹状体中高度表达,在那里它们与腺苷 A 受体(AR)形成异聚体。已有报道称精神分裂症患者死后组织中 AR-DR 异聚体密度发生变化,但 AR 在精神分裂症中的参与程度以及抗精神病药物的作用尚不清楚。在这里,我们使用 NanoBiT 检测法研究了三种典型抗精神病药物对哺乳动物细胞中 AR-DR 异聚化的影响。暴露 16 小时后,发现氟哌啶醇和阿立哌唑可使 AR-DR 异聚体密度显著增加,但氯氮平则无此作用。另一方面,氯氮平在治疗 2 小时后可使 AR-DR 异聚化显著降低,而氟哌啶醇或阿立哌唑则无此作用。这些化合物的计算结合模型揭示了独特的分子特征,解释了它们对异聚化的不同影响。氯氮平的庞大三环部分取代了 DR 的跨膜 5 区,导致与 AR 发生冲突,而氟哌啶醇和阿立哌唑的扩展结合模式稳定了 DR 第二个细胞外环的特定构象,增强了与 AR 的相互作用。有人提出,AR-DR 异聚化增加与抗精神病药物的锥体外系副作用(EPS)有关,氯氮平介导的 AR-DR 异聚化的特异性不稳定可以解释其低 EPS 倾向。